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The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration, and COX-2
expression and survival was examined in patients with transitional cell carcinoma of the urinary bladder (n¼103). Sixty-one patients
had superficial disease and 42 patients had invasive disease. Cancer-specific survival was shorter in those patients with invasive
compared with superficial bladder cancer (Po0.001). On univariate analysis, stratified by stage, increased Ki-67 labelling index
(Po0.05), increased COX-2 expression (Po0.05), C-reactive protein (Po0.05) and adjuvant therapy (Po0.01) were associated
with poorer cancer-specific survival. On multivariate analysis of these significant factors, stratified by stage, only C-reactive protein
(HR 2.89, 95% CI 1.42–5.91, P¼0.004) and adjuvant therapy (HR 0.29, 95% CI 0.14–0.62, P¼0.001) were independently
associated with poorer cancer-specific survival. These results would suggest that tumour-based factors such as grade, COX-2
expression or T-lymphocytic infiltration are subordinate to systemic factors such as C-reactive protein in determining survival in
patients with transitional cell carcinoma of the urinary bladder.
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Bladder cancer is the fourth most common malignancy in the
Western World. In the UK, there are 12500 new cases each year
and 5000 deaths annually (CancerStats, 2002). The mortality from
transitional cell carcinoma of the urinary bladder increases
significantly with the progression of superficial to invasive disease.
One of the common prognostic marker in clinical use is tumour
grade, which is subject to considerable intra- and interobserver
variation. Therefore, monitoring the possible progression of
superficial transitional cell carcinomas constitutes a significant
proportion of the general urological consultants’ workload.
It is now recognised that disease progression is dependent on a
complex interaction of the tumour and the host inflammatory
response (Balkwill and Mantovani, 2001; Coussens and Werb 2002;
Vakkila and Lotze 2004). Recently, the systemic inflammatory
response, as evidenced by elevated circulating concentrations of
C-reactive protein, has been shown to be independently associated
with poorer survival in patients with advanced cancer (O’Gorman
et al, 2000; Forrest et al, 2003; Maltoni et al, 2005). There is also
evidence that C-reactive protein has independent prognostic value
in primary operable cancer (Ikeda et al, 2003; McMillan et al, 2003;
Jamieson et al, 2005; Crumley et al, 2006; Lamb et al, 2006).
Therefore, it would appear that the systemic inflammatory
response is of considerable importance in the relationship between
the tumour, the host and outcome in patients with cancer.
Recently, we have reported that an elevated C-reactive protein was
associated with poor cancer-specific survival in patients with
bladder cancer independent of tumour stage and grade (Hilmy
et al, 2005).
The basis of the independent relationship between an elevated
C-reactive protein concentration and poor survival in cancer is not
clear. There are a number of possible explanations. Firstly, that an
elevated C-reactive protein identifies tumours capable of produ-
cing significant amounts of proinflammatory cytokines, in
particular interleukin-6 (Kinoshita et al, 1999; McKeown et al,
2004) and therefore with the potential for more rapid growth of
tumour cells (Jee et al, 2001; Trikha et al, 2003). Alternatively, C-
reactive protein could directly impair immune function (Maccio
et al, 1998; Du Clos and Mold, 2004; Canna et al, 2005) allowing
unrestrained tumour growth and dissemination.
Precise localisation of pro-inflammatory cytokines such as
interleukin-6 to tumour cells or inflammatory cells within the
tumour, particularly in paraffin-embedded tissues, remains
problematical (Canna et al, 2005). However, tumour proliferative
activity has been reliably assessed using the Ki-67 labelling index
in a variety of solid tumours, including bladder cancer (Blanchet
et al, 2001; Habuchi et al, 2005). Also, infiltration of tumours with
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sT-lymphocytes has been reliably demonstrated in a variety of solid
tumours, including bladder cancer (Stavropoulos et al, 1998;
Bevers et al, 2004).
Central to the local inflammatory response is cyclooxygenase-2
and increased expression has been shown to be associated with
poor survival in a number of common solid tumours (Dannenberg
et al, 2001; Dannenberg and Subbaramaiah, 2003) including
bladder cancer (Shirahama et al, 2001; Shariat et al, 2003).
The aim of the present study was therefore to examine the
relationship between the systemic inflammatory response (C-
reactive protein), tumour proliferative activity (Ki-67), T-lympho-
cyte (CD4þ, CD8þ) infiltration, and COX-2 expression and
cancer-specific survival in patients with transitional cell carcinoma
of the bladder.
METHODS
Patients
A cross-sectional retrospective study of patients with biopsy-
proven transitional cell carcinoma and with a measurement of
C-reactive protein before transurethral resection of bladder
tumour in Glasgow Royal Infirmary between 1992 and 2001 was
carried out. Tumours were grouped according to whether they
were superficial (pTa, pT1 and CIS) or muscle invasive (pT2–
pT4). However, patients with pT1G3 were considered as muscle
invasive tumours as they are recognised to have a significantly
higher progression rate (Manoharan and Soloway, 2005). At this
time, no patient showed clinical evidence of infection, or other
inflammatory conditions. Tumour stage was assessed using the
1997 AJCC/UICC TNM classification (Sobin and Wittekind, 1997),
and tumour grade was performed according to the 1999 WHO
grading system (Busch and Algaba, 2002).
Routine laboratory measurement of patient’s serum for C-
reactive protein concentration was performed. The limit of
detection of the assay was a C-reactive protein concentration
lower than 5mgl
 1. The coefficient of variation, over the range of
measurement, was less than 5% as established by routine quality
control procedures. C-reactive protein measurement of greater
than 10mgl
 1 was considered to indicate the presence of systemic
inflammatory response (O’Gorman et al, 2000).
The Research Ethics Committee of North Glasgow NHS Trust
approved the study.
Immunohistochemistry
Blocks from the primary tumour were fixed in 10% buffered
formalin in saline and embedded in paraffin wax. One representa-
tive block of tumour was selected for each patient. Serial individual
sections (4mm) were cut and mounted on slides coated with
aminopropyltriethoxysilane for the immuno-histochemistry of Ki-
67, CD4þ and CD8þ T-lymphocytes and COX-2 expression.
Ki-67
Sections were immunostained using a streptavidin biotin techni-
que (Dako, Cambridgeshire, UK) as previously described (McNicol
et al, 1997). The primary antibody for Ki-67 was mouse
monoclonal antibody (Dako, Cambridgeshire, UK).
CD4þ and CD8þ T-lymphocytes
Sections were immunostained using the peroxidase-based Envision
technique (Dako, Cambridgeshire, UK) as described previously
(Bromwich et al, 2003). The primary antibody for CD4 was mouse
monoclonal (Vector, Peterborough, UK) and that for CD8 was
mouse monoclonal (Dako, Cambridgeshire, UK).
COX-2
Sections were immunostained using the biotinylated/streptavidin
peroxidase complex technique (Dako, Cambridgeshire, UK) as
previously described (Edwards et al, 2004). The primary antibody
was human monoclonal antibody (Cayman Chemical Co., Annbor,
Michigan, USA).
Morphometry
The percentages of Ki-67-reactive tumour cells were evaluated at
 400 magnification by scoring a minimum of 1000 tumour cells
in randomly selected fields (Ki-67 labelling index). Cases were
counted by two observers and the highest score was chosen as the
corresponding index.
Quantitative analysis of the lymphoid infiltrate was performed
using point counting (Anderson and Dunnill, 1965) with a random
sampling technique. With this method, the volume occupied by
any given component (volume density) is expressed as a
percentage of the total volume of the tissue. A 100-point ocular
grid was used at  400 magnification and 30 fields were counted
per case for CD4þ and CD8þ immunopositive cells. Only fields
within the tumour (including cancer cell nests and surrounding
tissue stroma) were counted. Any normal tissue on the slide was
excluded from the analysis.
Semiquantitative analysis of the COX-2 expression was scored
using a weighted histoscore method (Kirkegaard et al, 2006).
Histoscores were calculated from the sum of (1 % cells staining
weakly positive)þ(2 % cell staining moderately positive)
þ(3 % cells staining strongly positive) with a maximum of 300.
The mean of the two observers’ scores were used for the analysis
as previously described (Edwards et al, 2004; Witton et al, 2004).
The observers (MH and RC) were blinded to the clinical
outcome of the patient.
Statistical analysis
Data are presented as median and range. For the purpose of
analysis, the tumour Ki-67 labelling index, CD4þ and CD8þ T-
lymphocyte counts and COX-2 expression were grouped by
tertiles. The relationships between these and other variables were
analyzed using the Mantel–Haenszel (w
2) test for trend and
Spearman’s rank correlation as appropriate.
Survival analysis was performed using the Cox proportional
hazard model. Multivariate survival analysis was performed using
stepwise backward procedure to derive a final model of the
variables that had a significant independent relationship with
survival. To remove a variable from the model, the corresponding
P-value had to be greater than 0.10. Deaths up to 31 August 2005
have been included in the analysis. Analysis was performed using
SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of patients with bladder cancer (n¼103)
that were grouped according to stage are shown in the Table 1.
The majority of patients were male, over the age of 65 years,
had superficial disease and were with elevated C-reactive
protein concentration preoperatively. Patients with invasive
bladder cancer were older (Po0.01) and had higher grade
tumours (Po0.001), increased Ki-67 labelling index (Po0.001),
increased tumour expression of COX-2 (Po0.001) compared
with superficial disease. Also, patients with invasive disease had
lower tumour infiltration of CD4þ (Po0.05) and CD8þ
T-lymphocytes (Po0.01) and had evidence of a systemic
inflammatory response (Po0.05). Patients with invasive
bladder cancer received more additional therapy (Po0.05).
In total, 22 patients had additional therapy (seven cystectomy,
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(BCG)). Cancer-specific survival was shorter in those patients
with invasive bladder cancer compared with superficial bladder
cancer (Po0.001).
The median follow-up of the survivors was 60 months. During
the course of the study, 66 patients died, 42 patients of their cancer
and 24 of intercurrent disease. On univariate analysis, stratified by
stage, increased Ki-67 labelling index (Po0.05), increased COX-2
expression (Po0.05), C-reactive protein (Po0.05) and no adjuvant
therapy (Po0.01) were associated with poorer cancer-specific
survival (Table 2).
On multivariate analysis of these significant factors, stratified by
stage, only C-reactive protein (HR 2.89, 95% CI 1.42–5.91,
P¼0.004) and no adjuvant therapy (HR 0.29, 95% CI (0.14–0.62,
P¼0.001) was independently associated with poorer cancer-
specific survival. When C-reactive protein was excluded from the
multivariate analysis, stratified by stage, only Ki-67 labelling index
(HR 1.56, 95% CI 0.99–2.45, P¼0.045) and adjuvant therapy (HR
0.41, 95% CI 0.19–0.86, P¼0.019) were independently associated
with poorer cancer-specific survival.
The inter-relationships between the clinicopathological char-
acteristics are shown in Table 3. In all patients, tumour grade was
directly associated with Ki-67 labelling index (Po0.001), COX-2
expression (Po0.001), CD4þ (Po0.01) and CD8þ (Po0.001)
T-lymphocytes, but not with C-reactive protein (P¼0.152). The
Ki-67 labelling index was directly associated with COX-2 expres-
sion (Po0.001), CD4þ (Po0.001) and CD8þ (Po0.01)
T-lymphocytes and, and also with C-reactive protein (P¼0.039).
The tumour COX-2 expression was directly associated with the
tumour CD4þ (Po0.01) and CD8þ (Po0.05) T-lymphocytic
infiltrate and weakly with C-reactive protein (P¼0.068). The
tumour CD4þ T-lymphocytic infiltrate was directly associated
with CD8þ (Po0.001) but not with C-reactive protein (P¼0.556).
The tumour CD8þ T-lymphocytic infiltrate was not associated
with C-reactive protein (P¼0.892).
DISCUSSION
In the present study, tumour grade and Ki-67 labelling index
were associated with increased tumour COX-2 expression and
infiltration by CD4þ and CD8þ T-lymphocytes in patients
with transitional cell carcinoma of the bladder. However, on
univariate analysis, only increased Ki-67 labelling index and
COX-2 expression were significantly associated with poorer
cancer-specific survival. However, neither of these tumour-based
factors was independently significant when a marker of the
systemic inflammatory response (C-reactive protein) was included
in the survival analysis. Therefore, the present study examines,
for the first time, the relationship between the preoperative
systemic inflammatory response and tumour-based factors and
suggests that the systemic inflammatory response is more closely
related to outcome in patients with transitional cell carcinoma
of the bladder.
These results are consistent with the superior prognostic value
of C-reactive protein compared with tumour T-lymphocytic
Table 1 Relationship between tumour stage and clinicopathological characteristics in patients with bladder cancer
Superficial (n¼61) Invasive (n¼42) P-value
Age group (p65/465 years) 30/31 10/32 0.010
Sex (male/female) 44/17 26/16 0.277
Tumour grade
G1/G2/G3 26/32/3 0/6/36 o0.001
Ki-67 (tertiles 1, 2, 3) 20/30/11 5/14/23 o0.001
COX-2 (tertiles 1, 2, 3) 31/25/5 4/9/29 o0.001
% Tumour volume T-lymphocytes
CD4+ (tertiles 1, 2, 3) 25/21/15 10/13/19 0.022
CD8+ (tertiles 1, 2, 3) 26/21/14 9/13/20 0.005
C-reactive protein (p10/410mgl
 1) 32/29 13/29 0.031
Adjuvant therapy (no/yes) 53/8 28/14 0.014
Cancer-specific survival (months) 109 (94–125)
a 41 (24–58)
a o0.001
aMean (95% CI).
Table 2 Relationship between clinicopathological characteristics and cancer-specific survival, stratified by stage, in patients with bladder cancer; univariate
survival analysis
Patients (n¼103) Hazard ratio (95%CI) P-value
Age group (p65/465 years) 40/63 1.52 (0.76–3.02) 0.234
Sex (male/female) 70/33 0.72 (0.37–1.39) 0.322
Tumour grade
G1/G2/G3 26/38/39 1.18 (0.57–2.48) 0.653
Ki-67 (tertiles 1, 2, 3) 34 (2–78)
a 1.73 (1.11–2.72) 0.017
COX-2 (tertiles 1, 2, 3) 200 (100–300)
a 1.95 (1.11–3.42) 0.020
% Tumour volume T-lymphocytes
CD4+ (tertiles 1, 2, 3) 2.70 (0–12.30)
a 1.26 (0.84–1.88) 0.260
CD8+ (tertiles 1, 2, 3) 2.20 (0.16–10.20)
a 1.27 (0.87–1.86) 0.221
C-reactive protein (p10/410mgl
 1) 45/58 2.36 (1.17–4.74) 0.016
Adjuvant therapy (no/yes) 81/22 0.36 (0.17–1.75) 0.006
aMedian (range).
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sinfiltration in patients with primary operable colorectal cancer
(Canna et al, 2005). One possible explanation is that C-reactive
protein can be measured with greater accuracy and precision than
tumour-based factors. Alternatively, it may be that C-reactive
protein plays a more pivotal role in the tumour–host relationship.
C-reactive protein is recognised to be an activator of innate
immunity and a modulator of adaptive immunity (Du Clos and
Mold, 2004) and its elevation is a precursor to progressive
involuntary loss of weight and lean tissue, which are believed to be
key factors in determining cancer survival (McMillan et al, 1998;
Kotler, 2000).
The results of the present study do not exclude nonmalignant
causes of an elevated C-reactive protein in patients with
transitional cell carcinoma of the urinary bladder. However, it is
of interest that C-reactive protein concentrations above the
threshold used in the present study (410mgl
 1) are rare
(o5%) in the general elderly population in the West of Scotland
(O’Reilly et al, 2006).
Therefore, it may be that an elevated C-reactive protein
concentration would be a useful marker of the host inflammatory
response, in addition to other risk factors, to stratify patients into
specific follow-up regimes. If further prospective studies show this
to be the case, it may therefore reduce the workload and anxiety in
those patients with superficial bladder cancer in whom continuous
follow-up is the norm despite less than 50% probability of tumour
recurrence.
These results are consistent with previous studies that
have examined the prognostic value of Ki-67 labelling index
(Habuchi et al, 2005). Similarly, in the largest studies, tumour
COX-2 expression has been shown to be significantly associated
with survival on univariate but not multivariate analyses
(Shirahama et al, 2001; Shariat et al, 2003). However, to our
knowledge there have been no studies that have examined the
relationship between tumour CD4þ and CD8þ T-lymphocytic
infiltration and cancer-specific survival in patients with bladder
cancer.
The results of the present study are consistent with the concept
that there is an active immune response to tumour cell
proliferation in these patients and that proliferative activity and
COX-2 expression may play a role in disease progression. It is
therefore of interest that intravesical treatment of superficial
carcinoma with BCG vaccine appears to reduce both disease
recurrence and progression (Lamm, 2000). It may be that those
patients with a high Ki-67 labelling index and COX-2 expression
and a marked lymphocytic infiltration will have a better response
to BCG (Alexandroff et al, 1999; O’Donnell, 2005).
In summary, the results of the present study shows that, in
addition to grade and Ki-67 labelling index, both local (tumour
COX-2 expression) and systemic (C-reactive protein) markers of
the inflammatory response were associated with poor cancer-
specific survival. However, on multivariate analysis only C-reactive
protein had independent prognostic value in patients with
transitional cell carcinoma of the urinary bladder.
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